Form 4: Ideaya Biosciences' Chief Medical Officer, Darrin Beaupre, Acquires 185,000 Stock Options

Darrin Beaupre, Chief Medical Officer of Ideaya Biosciences, acquired 185,000 stock options at an exercise price of $20.24 on February 27, 2025, according to a recent SEC Form 4 filing.

Summary

• On February 27, 2025, Darrin Beaupre, the Chief Medical Officer of Ideaya Biosciences, acquired 185,000 stock options.
• The exercise price for these options is $20.24 per share.
• The options vest over a four-year period, starting January 1, 2025, with 25% vesting on the first anniversary and the remainder vesting monthly thereafter.
• The options expire on February 26, 2035.

Sentiment

Score: 5

Explanation: Neutral. This is a routine filing related to executive compensation.

Industry Context

This is a standard practice for compensating and incentivizing key executives in publicly traded companies, particularly in the biotech industry.

Comparison to Industry Standards

• Stock option grants are a common component of executive compensation packages in the biotechnology industry.
• The vesting schedule of 25% after one year and then monthly is a typical vesting schedule.
• Comparing the size of the grant to similar companies would require further analysis of Ideaya's compensation strategy and peer group.

Stakeholder Impact

• The stock option grant aligns the executive's interests with those of the shareholders.
• The vesting schedule incentivizes long-term commitment from the executive.

Key Dates